FDA Times Patent Clock for Life-Saving Pulmonary Valve
Published Date: 6/25/2025
Notice
Summary
The FDA has officially set the review period for the EDWARDS SAPIEN 3 Transcatheter Pulmonary Valve, helping the company extend its patent protection. This means the makers get more time to keep their invention exclusive, which can impact when generic versions hit the market. Patients and competitors should watch for these changes as they affect device availability and innovation timing.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Manufacturer Can Seek Patent Extension
The FDA has determined the regulatory review period for the EDWARDS SAPIEN 3 Transcatheter Pulmonary Valve, which lets the manufacturer submit an application to the U.S. Patent and Trademark Office to extend its patent protection. This gives the company more time to keep the device exclusive before competitors can sell similar products.
Potential Delay of Competing Devices
Because the FDA set the regulatory review period and the company can seek a patent extension, competing or generic versions of the EDWARDS SAPIEN 3 device may be delayed from entering the market. Patients and competitors should watch this change because it can affect device availability, competition, and the timing of lower-cost alternatives.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in